Sun.Sep 15, 2024

article thumbnail

Ten-year survival data show long-term benefit of immunotherapy in melanoma

BioPharma Drive: Drug Pricing

Final follow-up results suggest Opdivo and Yervoy could be close to a cure for some people with advanced melanoma, shifting how doctors administer follow-up care.

Doctors 121
article thumbnail

Ovarian Cancer in the Family? Know Your Risks

Drugs.com

SUNDAY, Sept. 15, 2024 -- Nearly a quarter of all ovarian cancers are fueled by family genetics, so what should you do if your mom or sister are diagnosed?According to one expert, knowing whether you are at high risk is the first step toward taking.

98
article thumbnail

The Greatest Trick the Devil Ever Pulled was Convincing the World He Didn’t Exist: Senate Judiciary Set to Mark-Up Patent Reform Bills that Could Significantly Affect Hatch-Waxman and the BPCIA

FDA Law Blog: Biosimilars

By Kurt R. Karst — “Inter Partes Review” and “Section 101” are not terms you typically run into on this all-things-FDA blog, but we have talked about such patent-related issues before ( here and here ), and they are important legal (patent) principles, particularly in the context of drug and biological products (and the Hatch-Waxman Amendments and the Biologics Price Competition and Innovation Act (“BPCIA”)).